BioAge Labs, Inc. (NASDAQ: BIOA) reported an insider transaction involving Chief Medical Officer Paul D. Rubin on April 1, 2026. Rubin sold 8,820 shares of the company's common stock at a price of $17.81 per share, producing gross proceeds of $157,084. At the time of the sale the stock was trading near $17.50, after a roughly 415% gain over the prior 12 months.
On the same date, Rubin also exercised option awards to acquire an aggregate of 8,820 shares of BioAge Labs common stock. Those option exercises involved two tranches with exercise prices of $4.11 and $6.57, creating a combined value for the exercises of $44,572.
According to InvestingPro analysis cited in company reporting, the stock currently appears overvalued versus its Fair Value and the company carries a market capitalization of $776.65 million. For investors seeking more granular metrics, a comprehensive Pro Research Report covering BIOA and more than 1,400 other U.S. equities is available through InvestingPro.
Separately, BioAge Labs has received a string of analyst commentary tied to its clinical programs and near-term data readouts. The company released fourth-quarter fiscal 2025 results and indicated that its clinical timelines across the pipeline remain on track.
Brokerage firms have reflected differing levels of bullishness on BioAge. Jefferies upgraded the stock to a Buy and lifted its price target to $62, citing the potential of BGE-102 in cardiovascular and ophthalmology indications. Oppenheimer reiterated an Outperform rating and set a $60 price target, characterizing BGE-102 as having potential to reduce cardiovascular risks. Piper Sandler initiated coverage with an Overweight rating and a $73 price target, pointing to robust Phase 1 data for BGE-102 across multiple patient groups.
Jefferies also reiterated Buy coverage in separate commentary, highlighting progress in BioAge's NLRP3 inhibitor program and noting that the company's cash runway has been extended to 2029. Oppenheimer specifically noted that the Phase 1 multiple ascending dose (MAD) readout for BGE-102 remains on schedule.
These developments have been accompanied by the insider activity detailed above and the valuation assessment from InvestingPro. Readers looking for deeper valuation and performance analysis can consult the InvestingPro Pro Research Report referenced earlier.